PE/VC  Alta Partners

http://www.altapartners.com





     Office Locations:

One Embarcadero Center, 37th Floor
San Francisco, CA 94111
Phone: 415-362-4022
Fax: 415-362-6178

 

Stages:

  • Early
  • Growth
  • Middle Market


 

Industries:

  • Communications & Networking
  • Life Sciences & Healthcare

  •  

    Description:

    Founded in 1996 by four of the senior partners of Burr, Egan, Deleage & Co., Alta Partners currently manages eight venture fund programs aggregating approximately $2.0 billion in committed capital. Initially an early stage firm, Alta entered later stage investing with the formation of Alta BioPharma I, a fund focused on growth stage private companies and young public companies in the life sciences sector. ACP IV marked Alta's shift towards a singular focus on life sciences investing. Alta Partners VIII, the firm's most recent fund, is the first stage-independent life sciences fund for Alta. AP VIII will target companies across the continuum, from company formation to later-stage companies, both private and public. Since its inception, Alta has invested over $1.4 billion in more than 145 life sciences companies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Adam Tomasi Ph.D. Principal
    Dan Janney Managing Director
    David H. Mack Ph.D. Director
    Ed Hurwitz Director
    Ed Penhoet Ph.D. Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      09/22/2017


      DispatchHealth


      CO


      $30,800,000


      Growth


      03/25/2017


      eGenesis


      MA


      $38,000,000


      Series A


      03/08/2017


      VertiFlex


      CA


      $40,000,000


      


     

    Portfolio companies include:


      7TM Pharma
        web link


      Ablynx
        web link


      Achaogen
        web link


      Allakos
        web link


      Applied Genetic Technologies (AGTC)
        web link


      Avid Radiopharmaceuticals
        web link


      Bioventus
        web link


      Cara Therapeutics
        web link


      Ceregene
        web link


      DispatchHealth
        web link


      eGenesis
        web link


      Esperion Therapeutics
        web link


      Excaliard Pharmaceuticals
        web link


      Genedata
        web link


      Immune Design
        web link


      Kite Pharma
        web link


      Lumena Pharmaceuticals
        web link


      MAKO Surgical
        web link


      PneumRx
        web link


      Sutro Biopharma
        web link


      Threshold Pharmaceuticals
        web link


      USGI Medical
        web link


      VertiFlex
        web link


      Virobay
        web link


      Xelerated
        web link


      Zafgen
        web link


      ZS Pharma
        web link


     

    Recent News: